Lazabemide
货号：
11640-5mg 基本售价：
364.0 元 规格：
5 mg
产品信息
概述| 货号 | 11640-5mg |
| 描述 | Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson’s disease.1 Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively.2 It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme.3 The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitroandex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson’s disease.1 |
| 别名 | Ro 19-6327/000; |
性能| 供应商 | Cayman |
| 应用文献 |
1.LeWitt, P.A., and Taylor, D.C. Protection against Parkinson’s disease progression: Clinical experience. Neurotherapeutics 5(2), 210-225 (2008).
2.Holford, N.H.G.,Guentert, T.W.,Dingemanse, J., et al. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. British Journal of Clinical Pharmacology 37(6), 553-557 (1994).
3.Cesura, A.M.,Gottowik, J.,Lahm, H.W., et al. Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. European Journal of Biochemistry 236, 996-1002 (1996).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 199.6 |
| 分子式 | C8H10ClN3O |
| CAS号 | 103878-84-8 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
